Principal Financial Group Inc. Has $200.10 Million Stock Position in Amgen Inc. $AMGN

Key Points

• Principal Financial Group increased its stake in Amgen by 3.2% in Q4 to 611,351 shares, a holding worth about $200.10 million (roughly 0.11% of the company).
• Amgen beat Q1 estimates with EPS of $5.15 (vs. $4.77 expected) and set FY2026 guidance of 21.70–23.10 EPS, near the Street's consensus of ~22.45.
• The company announced a quarterly dividend of $2.52 per share (annualized $10.08, ~3.1% yield) and plans a $300 million U.S. manufacturing investment in Puerto Rico to expand biologics capacity.

Principal Financial Group Inc. boosted its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 3.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 611,351 shares of the medical research company's stock after purchasing an additional 18,791 shares during the quarter. Principal Financial Group Inc. owned about 0.11% of Amgen worth $200,101,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in AMGN. Board of the Pension Protection Fund bought a new position in Amgen during the fourth quarter worth $26,000. Olistico Wealth LLC bought a new stake in Amgen in the fourth quarter valued at $33,000. Cloud Capital Management LLC bought a new stake in Amgen in the third quarter valued at $34,000. Ares Financial Consulting LLC acquired a new position in shares of Amgen during the fourth quarter valued at about $34,000. Finally, Saranac Partners Ltd acquired a new position in shares of Amgen during the third quarter valued at about $37,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company's stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.85% of the stock is currently owned by insiders.

Amgen Trading Up 1.8%

NASDAQ:AMGN opened at $329.59 on Wednesday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 0.90. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The company has a market cap of $177.87 billion, a PE ratio of 22.94, a PEG ratio of 3.08 and a beta of 0.44. The firm has a 50-day moving average of $357.16 and a 200-day moving average of $341.35.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analysts' expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities research analysts expect that Amgen Inc. will post 22.45 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. Amgen's payout ratio is presently 70.15%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on AMGN. UBS Group raised their target price on Amgen from $390.00 to $400.00 and gave the company a "buy" rating in a research note on Monday, April 13th. Canaccord Genuity Group initiated coverage on Amgen in a research note on Monday, April 20th. They set a "hold" rating and a $366.00 price target on the stock. Argus increased their price target on Amgen from $360.00 to $400.00 and gave the stock a "buy" rating in a report on Friday, February 6th. Leerink Partners reissued a "market perform" rating and issued a $355.00 price objective on shares of Amgen in a research note on Thursday, March 5th. Finally, Morgan Stanley set a $332.00 price objective on Amgen in a report on Friday. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $357.12.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a $300 million additional U.S. manufacturing investment (Puerto Rico) to expand biologics capacity and strengthen supply-chain resilience; investors tend to see such capital spending as supportive of long-term growth and reliability. Article Title
• Neutral Sentiment: Erste Group reaffirmed a "hold" rating on AMGN, signaling no change in near-term analyst conviction and limiting directional impact from that broker. Article Title
• Neutral Sentiment: Market/sector headwinds: healthcare stocks were softer in recent trading sessions, a background factor that can mute upside for AMGN even as company-specific news emerges. Article Title
• Negative Sentiment: Competitive risk: Viridian Therapeutics reported encouraging results for its chronic thyroid eye disease program, a potential rival to Amgen’s Tepezza — the data lifted Viridian shares and raises the probability of increased market competition for Tepezza sales over time. Article Title
• Negative Sentiment: Guggenheim trimmed its price target on AMGN to $340 (from $351) while keeping a Neutral rating — a modest lowering of upside that can cap near-term analyst-driven buying. Article Title

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.